Impact Biomedical achieves COVID-19 success with Equivir and 3F Biofragrance

Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. has announced proven in vitro success with Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. Impact Biomedical and Global Research and Discovery Group Sciences (GRDG), in independent Biosafety Level 3 containment facilities, challenged its compounds with the SARS-CoV-2 virus. Equivir proved successful as a treatment, as well as a prophylactic protecting the cells from infection by the virus. Currently, there are no COVID-19 prophylactics.

After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

At the Helmholtz Centre for Infection Research (HZI), scientists have succeeded for the first time in detecting SARS-CoV-2 viruses using the revolutionary Cantisense(TM) technology from Digital Diagnostics AG. Application for approval of the Digid Cantisense(TM) SARS-CoV-2 Test by the FDA has been submitted. Delivery of the first point-of-care tests is planned for July.

Cyber Company to Supply 50M Health "COVI-PASS(TM)"

- Cyber tech company signs technology deal to supply 50M "COVI-PASS(TM)" Digital Health Passports to 15 countries - VST Enterprises signs deal with digital health technology company - Circle Pass Enterprises - to supply its patented VCode(R) technologies to create the world's most secure digital health passport - COVI-PASS(TM) - Cyber Company is committed to working closely with governments & major stakeholders to deploy safe & trusted technology solution for COVID-19 pandemic

Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts

SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million).

Block Chain In Healthcare: A One-stop Solution?

BLOCKCHAIN: A technology that took the world by storm with bitcoin in 2008 has gone on to establish itself as one of the greatest innovations since the web itself, establishing its dominance in various sectors across the globe. In this article, we discuss about blockchain in healthcare: the benefits it provides, the problems it solves, the industry trends and much more.

Path-Away(R), Active Ingredient in Plant-Based, Alcohol-Free NatShield(TM) Hand Sanitiser Developed by Holista CollTech, Tested >99.99% Effective Against COVID-19 Surrogate

Path-Away(R), a plant-based natural active ingredient used in the alcohol-free NatShield(TM) hand sanitiser developed by Malaysia-based and Australia-listed Holista CollTech (ASX: HCT), has been tested by a leading U.K. bio-safety laboratory to be more than 99.99% effective against a surrogate of the COVID-19 novel coronavirus, Holista said today.

MicroPort CardioFlow Completes Raising New Round of Funds

On April 15, 2020, MicroPort Scientific Corporation (Stock code: 00853) ("MicroPort"), announced that MicroPort CardioFlow Medtech Corporation ("MicroPort CardioFlow"), which is a subsidiary of MicroPort, had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction of seven prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million. After this round of fundraising, the investors will have an aggregate shareholding of 10.83% in MicroPort CardioFlow. J.P. Morgan Securities (Asia Pacific) Limited and Citigroup Global Markets Asia Limited acted as co-placement agents in the transaction.

Fullerton Healthcare Redeems US$175m 7.0% Senior Perpetual Capital Securities, Underscoring Resilience Amidst COVID-19 Uncertainty

Fullerton Healthcare Corporation Limited ("Fullerton Health"), the leading integrated healthcare platform in the Asia Pacific, announces that it has fully redeemed its US$175 million senior perpetual capital securities today, underscoring its financial resilience and commitment to stakeholders amidst economic uncertainty arising from the COVID-19 pandemic.